Chiavarelli M, Boucek M M, Nehlsen-Cannarella S L, Gundry S R, Razzouk A J, Bailey L L
Department of Surgery, Loma Linda International Heart Institute, CA.
Arch Surg. 1992 Sep;127(9):1072-5; discussion 1075-6. doi: 10.1001/archsurg.1992.01420090080011.
Early age at cardiac transplantation may favor successful engrafting with minimal chronic immunosuppression. Fifty-two newborns underwent orthotopic heart transplantation; 47 (90%) survived the operation, and 44 (85%) were late survivors. Actuarial survival was 92% at 1 month, 86% at 1 year, and 84% at 5 years. Forty-four infants who survived 12 weeks and the corresponding 100 rejection episodes were analyzed. Mean follow-up was 2.2 years. The mean number of rejections per year of follow-up was 1.2. No episodes of rejection were identified in six patients. Seven patients had a late rejection episode more than 1 year after transplantation, and only one had a late rejection episode after 2 years. Neonatal cardiac transplantation is effective and durable therapy for uncorrectable heart disease. Intermediate-term results are excellent. Severe rejection is uncommon, and few episodes occur after 1 year of follow-up.
早期进行心脏移植可能有利于在最小程度的慢性免疫抑制下成功植入。52例新生儿接受了原位心脏移植;47例(90%)手术存活,44例(85%)为晚期存活者。1个月时的精算生存率为92%,1年时为86%,5年时为84%。对44例存活12周的婴儿及相应的100次排斥反应发作进行了分析。平均随访时间为2.2年。随访每年的平均排斥反应次数为1.2次。6例患者未发现排斥反应发作。7例患者在移植后1年以上出现晚期排斥反应发作,只有1例在2年后出现晚期排斥反应发作。新生儿心脏移植是治疗无法矫正的心脏病的有效且持久的疗法。中期结果极佳。严重排斥反应并不常见,随访1年后很少发生排斥反应发作。